This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Sarah Aebersold Biography and Net Worth

VP of BioLife Solutions

Presently, Sarah Aebersold is Vice President-Human Resources for BioLife Solutions, Inc.

She received a graduate degree from Seattle University.

What is Sarah Aebersold's net worth?: The estimated net worth of Sarah Aebersold is at least $1.64 million as of November 26th, 2024. Ms. Aebersold owns 60,484 shares of BioLife Solutions stock worth more than $1,643,350 as of December 3rd. This net worth evaluation does not reflect any other assets that Ms. Aebersold may own. Learn More about Sarah Aebersold's net worth.
How old is Sarah Aebersold?: Ms. Aebersold is currently 48 years old. There are 6 older executives and no younger executives at BioLife Solutions. The oldest executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who is 64 years old. Learn More on Sarah Aebersold's age.
How do I contact Sarah Aebersold?: The corporate mailing address for Ms. Aebersold and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Sarah Aebersold's contact information.
Has Sarah Aebersold been buying or selling shares of BioLife Solutions?: During the last ninety days, Sarah Aebersold has sold $10,574.65 in shares of BioLife Solutions stock. Most recently, Sarah Aebersold sold 216 shares of the business's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $27.20, for a transaction totalling $5,875.20. Following the completion of the sale, the insider now directly owns 60,484 shares of the company's stock, valued at $1,645,164.80. Learn More on Sarah Aebersold's trading history.
Who are BioLife Solutions' active insiders?: BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.
Are insiders buying or selling shares of BioLife Solutions?: In the last twelve months, insiders at the medical equipment provider sold shares 74 times. They sold a total of 135,966 shares worth more than $2,718,539.10. The most recent insider tranaction occured on November, 26th when CFO Troy Wichterman sold 581 shares worth more than $15,803.20. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.
Information on this page was last updated on 11/26/2024.

Sarah Aebersold Insider Trading History at BioLife Solutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/26/2024	Sell	216	$27.20	$5,875.20	60,484
10/30/2024	Sell	203	$23.15	$4,699.45	60,700
7/11/2024	Sell	187	$20.54	$3,840.98	61,496
7/1/2024	Sell	3,000	$21.03	$63,090.00	61,683
4/22/2024	Sell	410	$16.50	$6,765.00	65,085
4/18/2024	Sell	348	$15.31	$5,327.88	65,495
4/1/2024	Sell	4,000	$17.65	$70,600.00	65,843
2/21/2024	Sell	58	$17.35	$1,006.30	41,806
1/23/2024	Sell	336	$17.11	$5,748.96	41,864
7/24/2023	Sell	462	$19.50	$9,009.00	43,983
4/19/2023	Sell	292	$19.33	$5,644.36	42,059
1/19/2023	Sell	374	$22.93	$8,575.82	44,167
11/10/2022	Sell	38	$23.16	$880.08	32,091
10/28/2022	Sell	272	$21.76	$5,918.72	32,129
8/10/2022	Sell	40	$23.17	$926.80	32,401
7/22/2022	Sell	252	$17.85	$4,498.20	32,441
5/13/2022	Sell	40	$12.32	$492.80	32,693
4/21/2022	Sell	325	$13.94	$4,530.50	32,733
2/10/2022	Sell	197	$29.38	$5,787.86
1/20/2022	Sell	332	$30.24	$10,039.68
10/20/2021	Sell	272	$42.34	$11,516.48

Sarah Aebersold Buying and Selling Activity at BioLife Solutions

BioLife Solutions Company Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Today's Range

Now: $27.17

$26.62

$27.44

50 Day Range

MA: $24.27

$20.47

$27.47

2 Week Range

Now: $27.17

$12.45

$28.88

Volume

80,801 shs

Average Volume

387,822 shs

Market Capitalization

$1.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad